Compounds > atorvastatin
Page last updated: 2024-08-24

atorvastatin and montelukast

atorvastatin has been researched along with montelukast in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (42.86)29.6817
2010's4 (57.14)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Andricopulo, AD; Moda, TL; Montanari, CA1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY1
Dalvie, D; Loi, CM; Smith, DA1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Cheng, S; Ge, S; Liu, D; Liu, X; Xu, G; Xu, J; Zhou, G1
Cheng, S; Ge, S; Liu, D; Liu, X; Liu, Z; Xu, G; Zhang, R; Zhou, G; Zhu, W1

Reviews

1 review(s) available for atorvastatin and montelukast

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

6 other study(ies) available for atorvastatin and montelukast

ArticleYear
Hologram QSAR model for the prediction of human oral bioavailability.
    Bioorganic & medicinal chemistry, 2007, Dec-15, Volume: 15, Issue:24

    Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship

2007
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
    Chemical research in toxicology, 2012, Oct-15, Volume: 25, Issue:10

    Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding

2012
Which metabolites circulate?
    Drug metabolism and disposition: the biological fate of chemicals, 2013, Volume: 41, Issue:5

    Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations

2013
Anti-atherogenic effects of montelukast associated with reduced MCP-1 expression in a rabbit carotid balloon injury model.
    Atherosclerosis, 2009, Volume: 205, Issue:1

    Topics: Acetates; Animals; Atherosclerosis; Atorvastatin; Carotid Arteries; Catheterization; Chemokine CCL2; Cyclopropanes; Diet, Atherogenic; Disease Progression; Heptanoic Acids; Immunohistochemistry; Leukotriene Antagonists; Lipids; Male; Pyrroles; Quinolines; Rabbits; Random Allocation; Sulfides

2009
Montelukast inhibits matrix metalloproteinases expression in atherosclerotic rabbits.
    Cardiovascular drugs and therapy, 2009, Volume: 23, Issue:6

    Topics: Acetates; Animals; Atherosclerosis; Atorvastatin; Cyclopropanes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukotriene Antagonists; Lipids; Macrophages; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Myocytes, Smooth Muscle; Pyrroles; Quinolines; Rabbits; Random Allocation; Reverse Transcriptase Polymerase Chain Reaction; Sulfides

2009